Table 2.
Prevalence of clinically significant pituitary adenomas
| Author | Year | Country | Population | Adenomas | Prevalence, 1 per N | Prevalence, N per million | Female, % | Macro,% |
|---|---|---|---|---|---|---|---|---|
| Daly (230) | 2006 | Belgium | 71,972 | 68 | 1064 | 940 | 68 | 43 |
| Fontana (231) | 2009 | Switzerland | 55,000 | 44 | 1241 | 800 | NR | 44 |
| Fernandez (232) | 2010 | England | 81,149 | 63 | 1289 | 780 | 67 | 41 |
| Raappana (233) | 2010 | Finland | 242,400 | 164 | 1471 | 680 | 71 | 46 |
| Gruppetta (149) | 2013 | Malta | 400,000 | 316 | 1321 | 790 | 70 | 43 |
| Tjornstrand (234) | 2014 | Sweden | 1,590,640 | 592 | 2686 | 370 | 52 | 66 |
| Agustsson (223) | 2015 | Iceland | 330,000 | 471 | 865 | 1430 | 60 | 55 |
| Average | 1420 | 830 | 65 | 48 |
Abbreviations: Macro, macroadenoma; NR, not reported.